{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T17:40:18Z","timestamp":1782841218104,"version":"3.54.5"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2009,9,18]],"date-time":"2009-09-18T00:00:00Z","timestamp":1253232000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/2.0"},{"start":{"date-parts":[[2009,9,18]],"date-time":"2009-09-18T00:00:00Z","timestamp":1253232000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/2.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.1007\/s10637-009-9321-x","type":"journal-article","created":{"date-parts":[[2009,9,17]],"date-time":"2009-09-17T04:11:32Z","timestamp":1253160692000},"page":"844-853","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non\u2013small cell lung cancer"],"prefix":"10.1007","volume":"28","author":[{"given":"Isamu","family":"Okamoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryotaro","family":"Morinaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyasu","family":"Kaneda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshikazu","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taroh","family":"Satoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Kawada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Fukuoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Fukino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiko","family":"Tanigawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,9,18]]},"reference":[{"key":"9321_CR1","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3322\/CA.2007.0010","volume":"58","author":"A Jemal","year":"2008","unstructured":"Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ (2008) Cancer statistics, 2008. CA Cancer J Clin 58:71\u201396. doi:10.3322\/CA.2007.0010","journal-title":"CA Cancer J Clin"},{"key":"9321_CR2","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1200\/JCO.1997.15.8.2996","volume":"15","author":"The American Society of Clinical Oncology","year":"1997","unstructured":"The American Society of Clinical Oncology (1997) Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. Adopted on May 16, 1997 by the American Society of Clinical Oncology. J Clin Oncol 15:2996\u20133018","journal-title":"J Clin Oncol"},{"issue":"3 Suppl","key":"9321_CR3","doi-asserted-by":"publisher","first-page":"277S","DOI":"10.1378\/chest.07-1381","volume":"132","author":"MA Socinski","year":"2007","unstructured":"Socinski MA, Crowell R, Hensing TE, Langer CJ, Lilenbaum R, Sandler AB, Morris D, American College of Chest Physicians (2007) Treatment of non-small cell lung cancer, stage IV: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 132(3 Suppl):277S\u2013289S. doi:10.1378\/chest.07-1381","journal-title":"Chest"},{"key":"9321_CR4","doi-asserted-by":"publisher","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","volume":"64","author":"SM Wilhelm","year":"2004","unstructured":"Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA (2004) BAY 43\u20139006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099\u20137109. doi:10.1158\/0008-5472.CAN-04-1443","journal-title":"Cancer Res"},{"key":"9321_CR5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrc969","volume":"3","author":"J Downward","year":"2003","unstructured":"Downward J (2003) Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 3:11\u201322. doi:10.1038\/nrc969","journal-title":"Nat Rev Cancer"},{"key":"9321_CR6","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/j.bbamcr.2006.10.001","volume":"1773","author":"JA McCubrey","year":"2007","unstructured":"McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, Stivala F, Libra M, Basecke J, Evangelisti C, Martelli AM, Franklin RA (2007) Roles of the Raf\/MEK\/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 1773:1263\u20131284. doi:10.1016\/j.bbamcr.2006.10.001","journal-title":"Biochim Biophys Acta"},{"key":"9321_CR7","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1200\/JCO.2005.06.124","volume":"23","author":"D Strumberg","year":"2005","unstructured":"Strumberg D, Richly H, Hilger RA, Schleucher N, Korfee S, Tewes M, Faghih M, Brendel E, Voliotis D, Haase CG, Schwartz B, Awada A, Voigtmann R, Scheulen ME, Seeber S (2005) Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 23:965\u2013972. doi:10.1200\/JCO.2005.06.124","journal-title":"J Clin Oncol"},{"key":"9321_CR8","doi-asserted-by":"publisher","first-page":"5472","DOI":"10.1158\/1078-0432.CCR-04-2658","volume":"11","author":"JW Clark","year":"2005","unstructured":"Clark JW, Eder JP, Ryan D, Lathia C, Lenz HJ (2005) Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43\u20139006, in patients with advanced, refractory solid tumors. Clin Cancer Res 11:5472\u20135480. doi:10.1158\/1078-0432.CCR-04-2658","journal-title":"Clin Cancer Res"},{"key":"9321_CR9","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1038\/sj.bjc.6602584","volume":"92","author":"A Awada","year":"2005","unstructured":"Awada A, Hendlisz A, Gil T, Bartholomeus S, Mano M, de Valeriola D, Strumberg D, Brendel E, Haase CG, Schwartz B, Piccart M (2005) Phase I safety and pharmacokinetics of BAY 43\u20139006 administered for 21\u00a0days on\/7\u00a0days off in patients with advanced, refractory solid tumours. Br J Cancer 92:1855\u20131861. doi:10.1038\/sj.bjc.6602584","journal-title":"Br J Cancer"},{"key":"9321_CR10","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1093\/annonc\/mdi310","volume":"16","author":"M Moore","year":"2005","unstructured":"Moore M, Hirte HW, Siu L, Oza A, Hotte SJ, Petrenciuc O, Cihon F, Lathia C, Schwartz B (2005) Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43\u20139006, administered for 28\u00a0days on\/7\u00a0days off in patients with advanced, refractory solid tumors. Ann Oncol 16:1688\u20131694. doi:10.1093\/annonc\/mdi310","journal-title":"Ann Oncol"},{"key":"9321_CR11","doi-asserted-by":"publisher","first-page":"188","DOI":"10.3816\/CCC.2005.n.030","volume":"5","author":"P Kupsch","year":"2005","unstructured":"Kupsch P, Henning BF, Passarge K, Richly H, Wiesemann K, Hilger RA, Scheulen ME, Christensen O, Brendel E, Schwartz B, Hofstra E, Voigtmann R, Seeber S, Strumberg D (2005) Results of a phase I trial of sorafenib (BAY 43\u20139006) in combination with oxaliplatin in patients with refractory solid tumors, including colorectal cancer. Clin Colorectal Cancer 5:188\u2013196. doi:10.3816\/CCC.2005.n.030","journal-title":"Clin Colorectal Cancer"},{"key":"9321_CR12","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1093\/annonc\/mdl017","volume":"17","author":"H Richly","year":"2006","unstructured":"Richly H, Henning BF, Kupsch P, Passarge K, Grubert M, Hilger RA, Christensen O, Brendel E, Schwartz B, Ludwig M, Flashar C, Voigtmann R, Scheulen ME, Seeber S, Strumberg D (2006) Results of a Phase I trial of sorafenib (BAY 43\u20139006) in combination with doxorubicin in patients with refractory solid tumors. Ann Oncol 17:866\u2013873. doi:10.1093\/annonc\/mdl017","journal-title":"Ann Oncol"},{"key":"9321_CR13","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1158\/1078-0432.CCR-05-1571","volume":"12","author":"LL Siu","year":"2006","unstructured":"Siu LL, Awada A, Takimoto CH, Piccart M, Schwartz B, Giannaris T, Lathia C, Petrenciuc O, Moore MJ (2006) Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer. Clin Cancer Res 12:144\u2013151. doi:10.1158\/1078-0432.CCR-05-1571","journal-title":"Clin Cancer Res"},{"key":"9321_CR14","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1158\/1078-0432.CCR-06-1432","volume":"13","author":"B Escudier","year":"2007","unstructured":"Escudier B, Lassau N, Angevin E, Soria JC, Chami L, Lamuraglia M, Zafarana E, Landreau V, Schwartz B, Brendel E, Armand JP, Robert C (2007) Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and\/or metastatic renal cell carcinoma or malignant melanoma. Clin Cancer Res 13:1801\u20131809. doi:10.1158\/1078-0432.CCR-06-1432","journal-title":"Clin Cancer Res"},{"key":"9321_CR15","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1634\/theoncologist.12-4-426","volume":"12","author":"D Strumberg","year":"2007","unstructured":"Strumberg D, Clark JW, Awada A, Moore MJ, Richly H, Hendlisz A, Hirte HW, Eder JP, Lenz HJ, Schwartz B (2007) Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist 12:426\u2013437. doi:10.1634\/theoncologist.12-4-426","journal-title":"Oncologist"},{"key":"9321_CR16","doi-asserted-by":"publisher","first-page":"4836","DOI":"10.1158\/1078-0432.CCR-07-4123","volume":"14","author":"KT Flaherty","year":"2008","unstructured":"Flaherty KT, Schiller J, Schuchter LM, Liu G, Tuveson DA, Redlinger M, Lathia C, Xia C, Petrenciuc O, Hingorani SR, Jacobetz MA, Van Belle PA, Elder D, Brose MS, Weber BL, Albertini MR, O\u2019Dwyer PJ (2008) A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel. Clin Cancer Res 14:4836\u20134842. doi:10.1158\/1078-0432.CCR-07-4123","journal-title":"Clin Cancer Res"},{"key":"9321_CR17","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1111\/j.1349-7006.2008.00837.x","volume":"99","author":"H Minami","year":"2008","unstructured":"Minami H, Kawada K, Ebi H, Kitagawa K, Kim YI, Araki K, Mukai H, Tahara M, Nakajima H, Nakajima K (2008) Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors. Cancer Sci 99:1492\u20131498. doi:10.1111\/j.1349-7006.2008.00837.x","journal-title":"Cancer Sci"},{"key":"9321_CR18","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/j.1349-7006.2007.00648.x","volume":"99","author":"J Furuse","year":"2008","unstructured":"Furuse J, Ishii H, Nakachi K, Suzuki E, Shimizu S, Nakajima K (2008) Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. Cancer Sci 99:159\u2013165. doi:10.1111\/j.1349-7006.2007.00648.x","journal-title":"Cancer Sci"},{"key":"9321_CR19","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s00280-007-0639-9","volume":"61","author":"CH Takimoto","year":"2008","unstructured":"Takimoto CH, Awada A (2008) Safety and anti-tumor activity of sorafenib (Nexavar) in combination with other anti-cancer agents: a review of clinical trials. Cancer Chemother Pharmacol 61:535\u2013548. doi:10.1007\/s00280-007-0639-9","journal-title":"Cancer Chemother Pharmacol"},{"key":"9321_CR20","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205\u2013216. doi:10.1093\/jnci\/92.3.205","journal-title":"J Natl Cancer Inst"},{"key":"9321_CR21","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.ejca.2005.11.014","volume":"42","author":"D Strumberg","year":"2006","unstructured":"Strumberg D, Awada A, Hirte H, Clark JW, Seeber S, Piccart P, Hofstra E, Voliotis D, Christensen O, Brueckner A, Schwartz B (2006) Pooled safety analysis of BAY 43\u20139006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome? Eur J Cancer 42:548\u2013556. doi:10.1016\/j.ejca.2005.11.014","journal-title":"Eur J Cancer"},{"key":"9321_CR22","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.jaad.2008.06.034","volume":"60","author":"C Robert","year":"2009","unstructured":"Robert C, Mateus C, Spatz A, Wechsler J, Escudier B (2009) Dermatologic symptoms associated with the multikinase inhibitor sorafenib. J Am Acad Dermatol 60:299\u2013305. doi:10.1016\/j.jaad.2008.06.034","journal-title":"J Am Acad Dermatol"},{"key":"9321_CR23","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.jaad.2006.10.981","volume":"56","author":"JL MacGregor","year":"2007","unstructured":"MacGregor JL, Silvers DN, Grossman ME, Sherman WH (2007) Sorafenib-induced erythema multiforme. J Am Acad Dermatol 56:527\u2013528. doi:10.1016\/j.jaad.2006.10.981","journal-title":"J Am Acad Dermatol"},{"issue":"Suppl 1","key":"9321_CR24","first-page":"S97","volume":"3","author":"G Scagliotti","year":"2008","unstructured":"Scagliotti G, von Pawel J, Reck M, Cupit L, Cihon F, DiMatteo S, O\u2019Leary J, Hanna N (2008) Sorafenib plus carboplatin\/paclitaxel in chemonaive patients with stage IIIB-IV non-small cell lung cancer: Interim analysis results from the phase III, randomized, double-blind, placebo-controlled, ESCAPE (Evaluation of Sorafenib, Carboplatin, and Paclitaxel efficacy in NSCLC) trial. J Thoracic Oncol 3(Suppl 1):S97\u2013S98","journal-title":"J Thoracic Oncol"},{"key":"9321_CR25","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/S0022-3565(25)12102-2","volume":"275","author":"DS Sonnichsen","year":"1995","unstructured":"Sonnichsen DS, Liu Q, Schuetz EG, Schuetz JD, Pappo A, Relling MV (1995) Variability in human cytochrome P450 paclitaxel metabolism. J Pharmacol Exp Ther 275:566\u2013575","journal-title":"J Pharmacol Exp Ther"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-009-9321-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-009-9321-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-009-9321-x.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-009-9321-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T06:48:13Z","timestamp":1739342893000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-009-9321-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9,18]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["9321"],"URL":"https:\/\/doi.org\/10.1007\/s10637-009-9321-x","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,9,18]]},"assertion":[{"value":"7 August 2009","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2009","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2009","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}